ABSTRACT
INTRODUCTION
Pyrazinamide (PZA) is a cornerstone first-line anti-tuberculosis compound commonly also used in second-line therapeutic treatment of multi-drug resistant Mycobacterium tuberculosis (MTB) infection in humans. The drug is a structural analogue of nicotinamide, requiring conversion into its active form, i.e., pyrazinoic acid, by the enzyme pyrazinamidase/nicotinamidase (PZase) (1, 2) . PZase is encoded by the MTB pncA gene (561 bp) (2) . It has been postulated that the mechanism of action of PZA is through pyrazinoic acid, causing disruption of bacterial membrane mediated energetics and ultimately inhibition of membrane transport (3) . The contribution of PZA to the killing of MTB as part of a multidrug regimen for the treatment of tuberculosis (TB) is considerable, and its inclusion with rifampicin in anti-TB therapeutic regimens resulted in significant shortening of treatment duration from 18 to 6 months (3). The drug is known to specifically target semi-dormant bacteria that are not killed by other antituberculosis drugs (4, 5) .
Mutations in the pncA gene are associated with phenotypically pyrazinamide-resistant isolates of MTB (2, 6, 7) . Such mutations can occur in the promoter or coding regions, and result in amino acid substitutions, frameshifts, or stop codon mutations. Furthermore, phenotypic resistance has been reported in the literature for isolates containing the wild-type gene suggesting the existence of a possible additional gene location involved in pyrazinamide resistance (2, 8) .
Inclusion of pyrazinamide in second-line treatment regimens for multi-drug resistant (MDR) cases of TB is rarely based on PZA susceptibility status of clinical isolates mainly because phenotypic assays are difficult to perform. This is primarily due to the drug being active only in an acid medium posing challenges to drug susceptibility testing (DST) in the clinical laboratory (4, 9) . Phenotypic methods for susceptibility testing of MTB to pyrazinamide, and specifically the use of the Bactec 960 Mycobaterium Growth Indicator Tube (MGIT) liquid culture test system is currently regarded as the 'gold standard' for determination of PZA resistance (10) . Recent guidelines, however, recommend use of the PZA test kit for MGIT 960 (11) .
Two recent studies in South Africa revealed that 52 % of all multidrug-resistant M. tuberculosis (MDR-TB) isolates carry resistance-conferring pncA gene mutations. (5, 12). In addition, the Bactec 460 radiometric culture assay and the Wayne enzymatic assay that measure loss of pyrazinamidase activity as a measure of resistance indicated marked discrepancies to Sanger sequencing in identifying resistance to PZA (12) . 4 Currently, there is a clear need to more accurately define the nature of PZA resistance at the genotypic level, and in particular assessing the potential impact of PZA resistance on treatment outcomes in patients if judged by currently available and emerging technologies. In this study, using Ion Torrent next-generation sequencing (NGS) and the Bactec 960 MGIT liquid culture assay, we reinvestigated a collection of MTB isolates previously studied and characterized for PZA resistance using the Bactec 460 radiometirc assay, the Wayne test, and Sanger sequencing (12) . We also aimed to detect heteroresistance by NGS, i.e. the co-existence of susceptible and resistant strains in the same isolate, as a possible cause of discrepant results between tests.
MATERIALS AND METHODS

Description of isolates.
A national survey of drug resistance in M. tuberculosis isolates from pulmonary cases of TB was conducted between 2001 and 2002 in South Africa (12) . All isolates from a survey collection of 5866 isolates were tested for susceptibility to rifampicin (RIF), isoniazid (INH), streptomycin (STM) and ethambutol (EMB). Of these, 179 were labelled as multi-drug resistant (9.9% of these designated resistant to all four test drugs). All specimens were collected from South African patients, across eight of the nine provinces in the country.
The 179 MDR-TB isolates were stored in Greave's media uninterrupted at -80°C freezer for 12 years since collection. Of these isolates, 130 were available for further investigation and 88 were successfully re-cultured after removal from storage. Frozen cultures were thawed for 24 hours, and 200 µl of each original culture suspension inoculated into Bactec 960 MGIT liquid culture media tubes. Only one passage was performed between Bactec 460 and MGIT 960 testing from original frozen cultures. The H37Rv reference strain was included as a positive control in this study. Pyrazinamide susceptibility of 86 of the 88 re-cultured isolates was previously 5 determined using the Bactec 460 TB System, whilst all 88 isolates had previously been tested using Wayne test and Sanger sequencing (10) . In this study, we re-investigated PZA susceptibility using the Bactec 960 MGIT PZA Test Kit as per manufacturer's instructions, and also applied NGS of the pncA gene for detection of confirmatory mutations.
MGIT positive isolates were checked for contamination by streaking on blood agar plates and incubating for 24 hours at 37°C. Following subculture, 0.5 ml MGIT medium containing MTB was transferred to 1. Mycobacterium tuberculosis inocula were transferred to a 1.5 ml micro-centrifuge tube. After thorough mixing and subsequent centrifugation, the entire supernatant was applied to a microextraction column, centrifuged for 1 minute at 13, 000 rpm, and the flow-through material was discarded. Wash buffer (200 µl) was applied to the extraction column, centrifuged for 1 min at 13,000 rpm, followed by further addition of wash buffer (200 µl) to the extraction column, with subsequent centrifuging in similar fashion as described above discarding the flowthrough material. Total MTB DNA was eluted by 1 minute centrifugation at maximum speed using 50 ul of pre-heated (~75C) elution solution. Total MTB DNA was stored at -20 C until and viewed using an Ultraviolet Transiluminator (Spectroline, Westberry, New York, USA).
Next-Generation Sequencing. Whole-gene next-generation Ion Torrent sequencing was performed using a novel but standardized M. tuberculosis protocol (14) . All PCR products were subjected to full-gene pncA sequencing. Library preparation was carried out using the Ion Ion Torrent detected mutations in 6 isolates that were not initially detected using Sanger sequencing (Table 3) , probably as a result of the shorter length of the genetic region targeted by Sanger sequencing.
One of these isolates exhibited double mixed mutations (L159P/L and T135P/T), three isolates exhibited (16) (17) (18) . Trans-translation is involved in degradation of potentially toxic protein products formed in stressed bacteria and is required for persistence and survival.
The panD gene encodes an aspartate decarboxylase involved in synthesis of β-alanine, a precursor of pantothenate and co-enzyme A (18).
Three isolates carried mutations in the pncA gene promoter region (T -10 C and T -12 C), and double mutations were noticed in three isolates. Additionally, there were seven heteroresistant isolates with both resistant and susceptible amino acid changes. Some isolates had D8N, K96STOP, and H71Y mutations. Amino acids Asp 8 and Lys 96 are part of the catalytic triad Cys138-Asp8-Lys96, and are important for catalytic activation of pncA activity. Amino acid His 71 is involved in metal ion binding (19) . This suggests that changes in these amino acids can result in PZA resistance in M. tuberculosis. Two isolates in this study exhibited the C14R mutation which is a high confidence mutation (15, 20) . In addition to C14R, mutation S164P is also listed by Miotto et al (20) as a mutation carrying a very high confidence (level A), serving as a prominent determinant of phenotypic PZA resistance. The confidence level of L151S as a resistance determinant, also detected in our study, is uncertain. We suggest that single gene NGS might be adequate to detect these high confidence mutations, and that whole genome sequencing is not necessarily required. 
